Goldman Sachs hosted a meeting with Pfizer Inc’s (NYSE:PFE) newly appointed Chief Scientific Officer Chris Boshoff (effective ...

Pharma vs pushes back as Senators look into telehealth moves, startups using AI for small molecule drugs, and more.

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

Is the healthcare stock in big trouble and headed for a greater decline, or are investors perhaps a bit too bearish on the ...

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

Padcev, a drug Pfizer acquired in 2023, is a part of the only chemo-free treatment for bladder cancer patients newly ...

Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United ...

In Hong Kong, the 20-valent Pneumococcal Conjugate Vaccine (PCV20) that offers the broadest serotype coverage of any ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and ...

Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...

One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Even though it posted some decent earnings numbers, investors can't shake the fear that the business is facing ...